Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ASP Isotopes (ASPI) Receivables (2023 - 2025)

ASP Isotopes has reported Receivables over the past 3 years, most recently at $20.2 million for Q4 2025.

  • On a quarterly basis, Receivables rose 2758.56% to $20.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.2 million, a 2758.56% increase, with the full-year FY2025 number at $20.2 million, up 2758.56% from a year prior.
  • Receivables reached $20.2 million in Q4 2025 per ASPI's latest filing, up from $18.4 million in the prior quarter.
  • The five-year high for Receivables was $20.2 million in Q4 2025, with the low at $216504.0 in Q1 2024.
  • The 3-year median for Receivables is $649476.0 (2025), against an average of $4.7 million.
  • The largest YoY upside for Receivables was 3184.55% in 2025 against a maximum downside of 26.0% in 2025.
  • Tracing ASPI's Receivables over 3 years: stood at $217000.0 in 2023, then skyrocketed by 225.81% to $707000.0 in 2024, then skyrocketed by 2758.56% to $20.2 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $20.2 million, $18.4 million, and $649476.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.